Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2016

01-11-2016 | Letter to the Editor

Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety

Authors: Thomas S. Y. Chan, Pek-Lan Khong, Yok-Lam Kwong

Published in: Annals of Hematology | Issue 11/2016

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A (2016) Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13(1):25–40CrossRefPubMed
2.
Michonneau D, Sagoo P, Breart B, Garcia Z, Celli S, Bousso P (2016) The PD-1 axis enforces an anatomical segregation of CTL activity that creates tumor niches after allogeneic hematopoietic stem cell transplantation. Immunity 44(1):143–54CrossRefPubMed
3.
Angenendt L, Schliemann C, Lutz M, Rebber E, Schulze AB, Weckesser M, Stegger L, Schäfers M, Groth C, Kessler T, Lenz G, Stelljes M, Berdel WE (2016) Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 51(3):443–5CrossRefPubMed
4.
Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP (2016) Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant(Feb 1) [Epub ahead of print]
5.
Herbaux C, Gauthier J, Brice P, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Thiebaut-Bertrand A, Demarquette H, Boyle E, Ysebaert L, Houot R, Yakoub-Agha I, Morschhauser F (2015) Preliminary results of a Phase I study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 126:3979
6.
Villasboas JC, Ansell SM, Witzig TE (2016) Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget 7(11):13260–13264PubMedPubMedCentral
7.
Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S, McGuirk JP, Abhyankar S (2016). Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma. Bone Marrow Transplant Apr 25 [Epub ahead of print]
8.
Kwong YL (2016) Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol 95(7):1191–2CrossRefPubMed
9.
Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Gutierrez M, Snyder E, Ricart AD, Balakumaran A, Moskowitz CH (2015) PD-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. Blood 126:584
10.
Kwong YL, Lopes D, Khong PL (2016). Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma. Br J Haematol Jan 15 [Epub ahead of print]
Metadata
Title
Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety
Authors
Thomas S. Y. Chan
Pek-Lan Khong
Yok-Lam Kwong
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2764-1

Other articles of this Issue 11/2016

Annals of Hematology 11/2016 Go to the issue

Letter to the Editor

Splenectomy in ITP: we keep removing a healthy functional organ

Original Article

Evaluation of neutrophil–lymphocyte ratio in patients with early-stage mycosis fungoides

Original Article

Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol

Letter to the Editor

Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants

Original Article

Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes

Original Article

Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits